Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Bolt Biotherapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −1 vs. Q2 2025
- Shares held
- 804.0K
- −83.5K (−9.4%) vs. Q2 2025
- Total value
- $4.28M
- −$819.0K (−16.1%) vs. Q2 2025
- New holders
- 3
- 2 more added
- Sold out
- 4
- 9 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 176,064 | $936.7K | 0.08% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 137,721 | $732.7K | 0.04% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 94,573 | $503.1K | 0.29% | 00.0% | Unchanged |
| Tang Capital Management LLC | 66,879 | $355.8K | 0.01% | −100,000−59.9% | Reduced |
| Nan Fung Group Holdings Ltd | 58,347 | $310.4K | 0.52% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 48,830 | $259.8K | 0.03% | −3,626−6.9% | Reduced |
| Board of Trustees of The Leland Stanford Junior University | 35,978 | $191.4K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 34,231 | $182.1K | 0.00% | −24,253−41.5% | Reduced |
| Pfizer Inc | 31,305 | $166.5K | 0.04% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 28,625 | $152.3K | 0.00% | +10,300+56.2% | Added |
| Geode Capital Management, LLC | 18,533 | $98.6K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 16,642 | $88.5K | 0.00% | +16,642 | New |
| Shay Capital LLC | 15,958 | $84.9K | 0.02% | +15,958 | New |
| Squarepoint Ops LLC | 14,836 | $78.9K | 0.00% | +2,448+19.8% | Added |
| DRW Securities, LLC | 12,322 | $65.6K | 0.00% | +12,322 | New |
| BlackRock, Inc. | 9,711 | $51.7K | 0.00% | −839−8.0% | Reduced |
| Morgan Stanley | 3,128 | $16.6K | 0.00% | −451−12.6% | Reduced |
| Tower Research Capital LLC (TRC) | 259 | $1.38K | 0.00% | −136−34.4% | Reduced |
| JPMorgan Chase & Co | 42 | $223 | 0.00% | −1−2.3% | Reduced |
| Bank of America Corp | 31 | $165 | 0.00% | −251−89.0% | Reduced |
| SBI Securities Co., Ltd. | 10 | $53 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 6 | $32 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $16 | 0.00% | −180−98.4% | Reduced |
| Salem Investment Counselors Inc | 2 | $11 | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −10,823−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −483−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −121−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1−100.0% | Sold out |